Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 16/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.34 |
| ▸ | GMNN | O75496 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.34 |
| ▸ | KDM5A | P29375 | 2/20 | 0.33 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.33 |
| ▸ | KDM5B | Q9UGL1 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4855605 | 0.83 | MAPT (0.41) | CRHR1LMNAMEN1NR1I2GMNN | |
| SCHEMBL4852680 | 0.79 | CRHR1 (0.50) | CRHR1LMNAMEN1NR1I2GMNN | |
| SCHEMBL4853995 | 0.78 | ALDH1A1 (0.42) | CRHR1LMNAMAPK1NPSR1KDM5A | |
| SCHEMBL19700421 | 0.72 | CRHR1 (0.42) | CRHR1LMNAMEN1NR1I2GMNN | |
| SCHEMBL4855812 | 0.71 | TSHR (0.46) | CRHR1LMNAMEN1CYP2C9TSHR | |
| SCHEMBL4852355 | 0.69 | CRHR1 (0.40) | CRHR1 | |
| SCHEMBL4846763 | 0.69 | SLC34A1 (0.46) | CRHR1 | |
| SCHEMBL4857708 | 0.68 | CRHR1 (0.49) | CRHR1LMNAMEN1NR1I2GMNN | |
| SCHEMBL4846780 | 0.67 | CRHR1 (0.40) | CRHR1MAPTTP53 | |
| SCHEMBL4848082 | 0.64 | TP53 (0.49) | CRHR1LMNATSHRKMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170355708-A1 | POTASSIUM CHANNEL MODULATORS | CADENT THERAPEUTICS, INC. | 2017-12-14 | — | — | US | disclosed |
| US-7414059-B2 | Pyrazolyl and imidazolyl pyrimidines as CRF antagonists | ROCHE PALO ALTO LLC (US) | 2008-08-19 | — | — | US | disclosed |
| US-7414059-B2 | Pyrazolyl and imidazolyl pyrimidines as CRF antagonists | ROCHE PALO ALTO LLC (US) | 2008-08-19 | — | — | US | disclosed |
| US-7414059-B2 | Pyrazolyl and imidazolyl pyrimidines as CRF antagonists | ROCHE PALO ALTO LLC (US) | 2008-08-19 | — | — | US | disclosed |
| US-20050113382-A1 | Spiro tetrahydroquinazolines and dihydrocyclopentapyrimidines as CRF antagonists | ROCHE PALO ALTO LLC | 2005-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355708-A1 | POTASSIUM CHANNEL MODULATORS | KCNJ11, KCNJ2, KCNJ1 | CRHR1 3535/4885LMNA 1523/4885MEN1 1414/4885 |
| US-20050113382-A1 | Spiro tetrahydroquinazolines and dihydrocyclopentapyrimidines as CRF antagonists | AVPR2, CRHR1, CRHR2 | CRHR1 2/4885LMNA 3003/4885MEN1 648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.